Free Trial
→ This simple indicator removes the “technical” out of technical trading (From ProsperityPub) (Ad)

Sigyn Therapeutics Q4 2022 Earnings Report

Sigyn Therapeutics logo
$4.12 0.00 (0.00%)
As of 02/21/2025
Earnings History

Sigyn Therapeutics EPS Results

Actual EPS
-$0.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Sigyn Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sigyn Therapeutics Announcement Details

Quarter
Q4 2022
Date
3/31/2023
Time
N/A

Conference Call Resources

Sigyn Therapeutics Earnings Headlines

Sigyn Therapeutics to Present at Tomorrow’s Small Cap Growth Virtual Investor Conference
February 5, 2025 | financialpost.com
Sigyn Therapeutics to Present at Tomorrow's Small Cap Growth Virtual Investor Conference
February 5, 2025 | globenewswire.com
The FED is losing the war on inflation
It's no longer just a “guesstimate” – Inflation is indeed getting worse. And although we want to believe the Fed has a good grip on it, they don't. Right now, the suits over there are caught between a rock and a hard place. Either they watch as inflation grows, or they tear it down and send us into a full-blown recession. The kicker here is that neither of these are good for you. Whichever pill we end up with, prices will still climb higher as the value of the dollar sinks lower. The only real way out for the regular person is to increase your earning power. By increasing your income to match prices as they flare up… You’ll stay ahead of the impending doom we're running face-first into. And if you're looking for a strategy to help increase your income in 2025… I've got just the thing for you! You see, last year, I was able to grow a $10k model account to a little over $63k with 100 trade alerts But I changed my trading rules and more than doubled my results on those 100 published trades. I'm now calling them Warped Options…
February 23, 2025 | WealthPress (Ad)
Sigyn Therapeutics Announces the Appointment of Michael Ryan to Its Board of Directors
January 29, 2025 | finance.yahoo.com
Sigyn Therapeutics, Inc. (SIGY)
December 21, 2024 | finance.yahoo.com
Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now
October 30, 2024 | markets.businessinsider.com
See More Sigyn Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sigyn Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sigyn Therapeutics and other key companies, straight to your email.

About Sigyn Therapeutics

Sigyn Therapeutics (OTCMKTS:SIGY), a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.

View Sigyn Therapeutics Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles